Abstract

The present invention relates to the use of staurosporine derivatives for the preparation of a drug for the treatment of FIP1L1-PDGFRα-induced myeloproliferative diseases, especially for the curative and/or prophylactic treatment of hypereosinophilic syndrome and hypereosinophilic syndrome with resistance to imatinib, and to a method of treating hypereosinophilic syndrome and hypereosinophilic syndrome with resistance to imatinib, or other diseases associated with FIPL1-PDGFRa or similar mutations that activate PDGFRα.